Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

Jitters over the health of the UK economy have been fuelled by today’s weaker-than-expected GDP release. September’s 0.1% ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...

The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

Cairo – GlaxoSmithKline (GSK Egypt) registered an annual growth in consolidated net profit after tax to EGP 105.82 million during the first nine months (9M) of 2024, versus EGP 46.73 million.

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

GSK collaborates closely with Canadian sites — such as hospitals and other health-care centres — to operationalize its trials ...